Anders Jack 4
4 · Revolution Medicines, Inc. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
Anders Jack
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-02−2,814→ 0 totalExercise: $2.68From: 2022-08-16Exp: 2028-09-26→ Common Stock (2,814 underlying) - Exercise/Conversion
Common Stock
2025-09-02$2.68/sh+2,814$7,542→ 116,128 total - Sale
Common Stock
2025-09-02$40.02/sh−4,762$190,560→ 113,314 total - Exercise/Conversion
Common Stock
2025-09-02$4.73/sh+1,948$9,214→ 118,076 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-03−3,189→ 0 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (3,189 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-02−1,948→ 3,189 totalExercise: $4.73From: 2023-08-09Exp: 2029-08-08→ Common Stock (1,948 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-03−2,049→ 15,418 totalExercise: $17.00From: 2024-02-12Exp: 2030-02-11→ Common Stock (2,049 underlying) - Exercise/Conversion
Common Stock
2025-09-03$4.73/sh+3,189$15,084→ 116,503 total - Exercise/Conversion
Common Stock
2025-09-03$17.00/sh+2,049$34,833→ 118,552 total - Sale
Common Stock
2025-09-03$40.17/sh−5,238$210,432→ 113,314 total
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
- [F2]Includes 54,213 RSUs.
- [F3]This transaction was executed in multiple trades in prices ranging from $40.00 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]This transaction was executed in multiple trades in prices ranging from $40.01 to $40.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.